JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Crinetics Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

31 2.18

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

30.81

Максимум

31.39

Ключови измерители

By Trading Economics

Приходи

-16M

-97M

Продажби

361K

361K

Марж на печалбата

-26,807.202

Служители

437

EBITDA

-17M

-110M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+133.95% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-262M

2.9B

Предишно отваряне

28.82

Предишно затваряне

31

Настроения в новините

By Acuity

45%

55%

134 / 375 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.07.2025 г., 17:53 ч. UTC

Значими двигатели на пазара

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25.07.2025 г., 15:58 ч. UTC

Печалби
Значими двигатели на пазара

Aon Shares Rise After 2Q Earnings Beat

25.07.2025 г., 15:08 ч. UTC

Значими двигатели на пазара

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25.07.2025 г., 21:40 ч. UTC

Пазарно говорене

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25.07.2025 г., 21:23 ч. UTC

Пазарно говорене

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25.07.2025 г., 20:40 ч. UTC

Печалби

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25.07.2025 г., 20:10 ч. UTC

Печалби

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25.07.2025 г., 19:56 ч. UTC

Печалби

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25.07.2025 г., 19:14 ч. UTC

Пазарно говорене

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25.07.2025 г., 19:10 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25.07.2025 г., 19:01 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25.07.2025 г., 18:45 ч. UTC

Пазарно говорене

Gold Ends Down Week on Lower Note -- Market Talk

25.07.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

Sale Could Fetch Around $1B, Sources Say -- WSJ

25.07.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

LVMH in Talks to Sell Marc Jacobs -- WSJ

25.07.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25.07.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25.07.2025 г., 17:38 ч. UTC

Значими двигатели на пазара

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25.07.2025 г., 17:26 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Extends Decline -- Market Talk

25.07.2025 г., 17:13 ч. UTC

Печалби

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25.07.2025 г., 16:46 ч. UTC

Печалби

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25.07.2025 г., 16:45 ч. UTC

Печалби

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25.07.2025 г., 16:27 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

25.07.2025 г., 16:02 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25.07.2025 г., 15:34 ч. UTC

Печалби

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25.07.2025 г., 15:06 ч. UTC

Пазарно говорене

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25.07.2025 г., 15:05 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25.07.2025 г., 14:45 ч. UTC

Пазарно говорене

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25.07.2025 г., 14:44 ч. UTC

Пазарно говорене

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25.07.2025 г., 14:36 ч. UTC

Пазарно говорене
Печалби

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Crinetics Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

133.95% нагоре

12-месечна прогноза

Среден 72.5 USD  133.95%

Висок 97 USD

Нисък 36 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Crinetics Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

10

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

30.39 / 33.46Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

134 / 375 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.